INTRODUCTION {#sec1-1}
============

Alpha-synuclein is a principal component of Lewy bodies and Lewy neurites, which are pathologic hallmarks of Parkinson\'s disease\[[@ref1][@ref2]\]. Alpha-synuclein is generally considered to play a role in synaptic activity\[[@ref3]\], although its function remains largely unknown. Mutations in three loci (A53T, A30P, and E46K)\[[@ref4][@ref5][@ref6]\] and multiplication\[[@ref7][@ref8]\] in the alpha-synuclein encoding gene have been recognized as causes of the inherited form of Parkinson\'s disease. Therefore, it is proposed that alpha-synuclein contributes to the pathogenesis of Parkinson\'s disease.

Alpha-synuclein is conventionally known as an intraneuronal protein. However, a series of studies demonstrated the presence of alpha-synuclein in extracellular fluids, possibly as a result of the unconventional exocytosis of intravesicular alpha-synuclein\[[@ref9]\]. The collected data suggest cytotoxic effects of the fibrillar aggregates\[[@ref10][@ref11]\] or the protofibrillar or oligomeric aggregates\[[@ref12]\] of extracellular alpha-synuclein. In addition, it has been shown that aggregated extracellular alpha-synuclein fibrils can be internalized in the cells and enhance the intracellular formation of protein inclusions, leading to cell death\[[@ref13]\]. Therefore, extracellular alpha-synuclein has been indicated as a treatment target of Parkinson\'s disease\[[@ref14]\], and passive immunization for alpha-synuclein has recently been attempted\[[@ref15][@ref16]\].

Conversely, there is emerging evidence suggesting that alpha-synuclein has also neuroprotective effects. In one study, extracellular alpha-synuclein treatment at nanomolar concentrations protected neurons against cellular stresses such as serum deprivation, oxidative stress, and excitotoxicity through the PI3/Akt signaling pathway\[[@ref17]\]. In a transgenic mouse model, the increased expression of alpha-synuclein prevented paraquat-induced dopaminergic cell degeneration\[[@ref18]\]. Endogenous alpha-synuclein induction by valproic acid showed protective effects against glutamate-induced excitotoxicity in rat cerebellar granule cells\[[@ref19]\]. Wild-type alpha-synuclein rescued dopaminergic cells from both acute and chronic cytotoxicity induced by rotenone and maneb whereas mutant alpha-synuclein did not\[[@ref20]\].

Thus far, it is uncertain as to whether alpha-synuclein plays a favorable role for neurons at physiologic concentrations, which are estimated to be from picomolar to nanomolar levels in cerebrospinal fluid\[[@ref9][@ref10]\]. In this study, we attempted to assess the effect of extracellular alpha-synuclein at nanomolar concentrations on neuronal survival in cultured dopaminergic cell lines.

RESULTS {#sec1-2}
=======

Effect of extracellular alpha-synuclein on cell viability in neuronally-differentiated SH-SY5Y (ndSHSY) cells {#sec2-1}
-------------------------------------------------------------------------------------------------------------

The effect of monomeric alpha-synuclein on the viability of undifferentiated SH-SY5Y (SHSY) cells and ndSHSY cells is shown in [Figure 1](#F1){ref-type="fig"}. In ndSHSY cells, viability was increased when they were treated with alpha-synuclein for 24 hours at 50 nmol/L (from 100% to 126.8%, *P* \< 0.001, data were presented as percentage of control) and at 100 nmol/L (from 100% to 120.2%, *P* = 0.001), while cell viability did not change significantly in cells treated with 1 μmol/L alpha-synuclein (*P* = 0.128). The change in cell viability was not observed in alpha-synuclein-treated SHSY cells ([Figure 1](#F1){ref-type="fig"}).

![Different effects of alpha-synuclein on cell viability in undifferentiated and neuronally-differentiated SH-SY5Y cells.\
Cell viability was not significantly increased in undifferentiated SH-SY5Y cells treated with alpha-synuclein (A) but significantly increased in neuronally-differentiated SH-SY5Y cells treated with nonomolar (50 and 100 nmol/L \[M\]) alpha-synuclein (B). Values are represented as mean ± SD for three independent experiments. ^a^*P* \< 0.05, ^b^*P* \< 0.01, *vs*. control (CON) group (Mann-Whitney *U* test).](NRR-8-3269-g002){#F1}

ndSHSY cell proliferation after alpha-synuclein treatment {#sec2-2}
---------------------------------------------------------

To see whether cell viability increased after alpha-synuclein treatment with increased cellular proliferation, cell proliferation was measured by determining the proportion of number of both 5-bromo-2'-deoxyuridine (BrdU) and 4',6-diamidino-2-phenylindole (DAPI)-positive cells to number of DAPI-positive cells in 100-fold microscopic filed (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). The proportion of BrdU-positive cells was decreased after addition of alpha-synuclein for 24 hours compared to control (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}).

![Cell proliferation after treatment with different concentrations of alpha-synuclein.\
(A) Control, (B) alpha-synuclein 50 nmol/L, (C) alpha-synuclein 100 nmol/L, (D) alpha-synuclein 1 μmol/L. 4',6-Diamidino-2-phenylindole (DAPI) staining (blue), 5-bromo-2'-deoxyuridine (BrdU) staining (red), × 100. Proportion of BrdU-positive cells was decreased after 24 hour alpha-synuclein treatment in neuronally-differentiated SH-SY5Y cells.](NRR-8-3269-g003){#F2}

![Effect of alpha-synuclein on cell proliferation in neuronally-differentiated SH-SY5Y cells.\
%BrdU incorporation was assessed by percentage of number of BrdU(+)/DAPI(+) cells and represented as percentage of control. %BrdU in corporation was decreased after alpha-synuclein treatment. Cell count was done in 100-fold microscopic field and values are represented as mean ± SD of three individual experiments. ^a^*P* \< 0.05, *vs*. control (CON) group (Mann-Whitney *U* test). BrdU: 5-Bromo-2'-deoxyuridine; DAPI: 4',6-diamidino-2-phenylindole.](NRR-8-3269-g004){#F3}

Involvement of Akt pathway in alpha-synuclein related ndSHSY cell survival {#sec2-3}
--------------------------------------------------------------------------

To identify the mechanisms underlying the effects of nanomolar extracellular alpha-synuclein on cell survival, we measured the level of both Akt and phosphorylated Akt in ndSHSY cells after treatment with 100 nmol/L alpha-synuclein for 24 hours. Results showed that, compared to control, level of phosphorylated Akt was up-regulated after treatment with 100 nmol/L alpha-synuclein for 24 hours ([Figure 4](#F4){ref-type="fig"}).

![Western blot analysis for AKT and phosphorylated AKT (p-AKT) after alpha-synuclein (α-SN) treatment.\
Level of p-AKT (60 kDA) increased in neuronally-differentiated SH-SY5Y cells treated with 100 nmol/L α-SN than in control (A). The mean band density of two independent experiments (B).](NRR-8-3269-g005){#F4}

DISCUSSION {#sec1-3}
==========

In the present study, nanomolar concentrations of alpha-synuclein increased ndSHSY cell survival, which was accompanied by an increase in Akt phosphorylation.

Cell viability was increased after treatment with nanomolar alpha-synuclein (at 50 and 100 nmol/L) in ndSHSY cells. The increased cell viability induced by alpha-synuclein could be attributed to the increased cell proliferation or cell protection against death. A BrdU immunoassay revealed a significant decrease in the proportion of BrdU-positive cells after the alpha-synuclein treatment at all concentrations (0 \[control\], 50, 100 nmol/L, 1 μM)). The decreased proportion of BrdU-positive proliferating cells might be caused by the increased proportion of BrdU-negative non-proliferating surviving cells. As a result, we could exclude a bias caused by the cell proliferation from the increased ndSHSY cell viability. However, the exact mechanism of the decrease in the proportion of proliferating cells remains as a subject for future research.

Cell viability in SHSY cells showed an uptrend at 50 nmol/L but the change was not statistically significant. However, Seo *et al*\[[@ref17]\] showed that extracellular alpha-synuclein plays a protective role in SHSY cells as well. Therefore, further studies under a stress condition using SHSY cells are required.

The Akt pathway is a major neuronal pro-survival pathway which is activated in response to growth factor, oxidative stress and nutrient deprivation. Some neuroprotective agents, such as caffeine and insulin-like growth factor 1, have been shown to afford significant anti-apoptotic effects in Parkinson\'s disease cellular models via the activation of PI3/Akt pathways\[[@ref21][@ref22]\]. The Akt pathway was also linked to the survival of various neurons via Bcl-2 and Bax\[[@ref17]\]. The Akt pathway is involved in the modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity on dopaminergic neurons lead by alpha-synuclein in the ventral midbrain\[[@ref23]\]. In our study, the increased p-Akt levels after the alpha-synuclein treatment indicated that the increased neuronal survival rate after the alpha-synuclein treatment is likely to be associated with the activation of the Akt pathway.

A nanomolar concentration of extracellular alpha-synucl-ein enhanced dopaminergic neuronal survival in our study; this effect disappeared when the level of alpha-synuclein reached a micromolar concentration. Our result is in line with a previous report which showed that a low concentration of alpha-synuclein protected neurons against various toxic insults such as hypoxia, oxidative stress, and glutamate toxicity *via* the PI3/Akt pathway, whereas a high concentration or overexpression of alpha-synuclein had a cytotoxic effect on neurons\[[@ref17]\].

The role of extracellular alpha-synuclein remains to be elucidated as regards the pathogenesis of Parkinson\'s disease. Although alpha-synuclein clearing by immunization was recently attempted\[[@ref15][@ref16][@ref24]\] as a novel treatment, our results allude to the possibility of an undesirable effect of alpha-synuclein clearing therapy on dopaminergic neurons.

Our study has still several limitations. First, it involved an *in vitro* condition, and the SHSY and ndSHSY cells we used could not precisely mirror real dopaminergic neurons *in vivo*. The effect of a nanomolar concentration of extracellular alpha-synuclein may be different in an *in vivo* condition, where neurons and glial cells interact with each other. Second, only the effect of the monomeric form of alpha-synuclein was evaluated in this study. In addition to the monomeric form of alpha-synuclein, various forms of alpha-synuclein such as the oligomer, fibril and aggregated alpha-synuclein exist in extracellular fluid. In fact, only a small portion of alpha-synuclein remains in the monomeric form in body fluids. Furthermore, modifications of alpha-synuclein such as truncation, ubiquitination, nitration and phosphorylation can have effects that differ from those in our results\[[@ref25]\]. Third, the internalization of extracellular alpha-synuclein into dopaminergic neuronal cells was not assessed in our study. Therefore, it was unclear whether the enhanced cell survival by alpha-synuclein was mediated by some form of interaction between extracellular alpha-synuclein and certain receptors of cells or by the internalization of extracellular alpha-synuclein into the cells.

In this study, we provide evidence that extracellular alpha-synuclein enhances neuronal survival at a nanomolar concentration and this effect is most likely mediated by the Akt pathway. To the best of our knowledge, this is the first report describing a beneficial effect of extracellular alpha-synuclein on neuronal survival excluding the effect of alpha-synuclein on cell proliferation. Our study can update the role of alpha-synuclein in neuronal cells and its involvement in Parkinson\'s disease and related diseases.

MATERIALS AND METHODS {#sec1-4}
=====================

Design {#sec2-4}
------

This is an *in vitro* study using human dopaminergic cell line (SHSY cells and ndSHSY cells).

Time and setting {#sec2-5}
----------------

This experiment was performed at the Neurology Laboratory of Biomedical Research Institute, Seoul National University Hospital, South Korea, from March to December in 2012.

Materials {#sec2-6}
---------

Monomeric alpha-synuclein 1:1 000 (ATGen, Seongnam, South Korea), 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenylt-ertazolium bromide (MTT) solution (Sigma-Aldrich, St. Louis, MO, USA), dimethyl sulfoxide (DMSO; Sigma-Aldrich), DAPI (1:300) vector and anti-β actin (1:500) (Sigma-Aldrich) were used. Primary antibodies include mouse anti-BrdU (1:300) (BD Biosciences, San Jose, CA, USA), rabbit anti-Akt (1:1 000) (Cell Signaling Technology, Boston, MA, USA), and rabbit anti-phosphorylated Akt (1:500) (Cell Signaling Technology). Secondary antibodies include Cy3 conjugated goat anti-mouse (1:100) antibody and anti-rabbit IgG (1:5 000) antibody.

Methods {#sec2-7}
-------

### Cell culture and treatment {#sec3-1}

The human SH-SY5Y neuroblastoma cell line was purchased from ATCC and they were maintained in Dulbecco\'s modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), 100 U/mL penicillin, 100 μg/μL streptomycin and 2 mL glutamine (Gibco BRL, Gaithersburg, MD, USA) at 37°C in 95% air/5% CO~2~. SHSY cells were treated with 50 μmol/L retinoic acid and cultured for 5 days for neuronal differentiation. Both SHSY and ndSHSY cells were treated with 50, 100 nmol/L and 1 μmol/L concentration of alpha-synuclein for 24 hours.

### Viability assay {#sec3-2}

Cell viability was determined by a mitochondrial enzyme-dependent reaction of MTT (Sigma-Aldrich). The cell suspensions (5 × 10^4^ cells/well) were maintained for 24 hours and then treated with 0, 50, 100 nmol/L, 1 μmol/L monomeric alpha-synuclein for 24 hours. The media was removed and MTT solution (200 μL/well) was added to each well. After 2.5 hours of incubation, the MTT solution was removed. The formazan precipitate was dissolved in DMSO and was shaken for 5 minutes in room air. The absorbance was measured at 540 nm (Beckman spectrophotometer) using PBS as a blank. Cell survival was expressed as percentage of control.

### BrdU incorporation and immunocytochemistry {#sec3-3}

After treatment with monomeric alpha-synuclein for 24 hours, the ndSHSY cells were labeled with 10 μmol/L BrdU solution and incubated for an additional 3 hours at 37°C. After the labeling medium was removed from the plates, the cells were fixed with 4% paraformaldehyde, MgCl~2~ and CaCl~2~ for 20 minutes. Subsequently, cells were treated with 1.5 mol/L HCl for 30 minutes, fixed with 4% paraformaldehyde in PBS for 20 minutes at room temperature, treated in 4% normal goat serum in PBS with 0.2% Triton X-100 for 1 hour at room temperature, and then incubated with a mouse anti-BrdU antibody (1:300; BD Biosciences) at 4°C overnight. PBS washes were performed between each step. After washing the plates, cells were incubated with goat anti-mouse IgG conjugated to a fluorescein Cy3 label (1:100, Vector) for 1 hour at 37°C. The nuclei were counterstained with DAPI. The number of cells was counted under × 100 magnification. The images were photographed using confocal microscopy (Leica Microsystems, Wetzlar, Germany).

### Western blot analysis for Akt and phosphorylated Akt {#sec3-4}

The cells were washed with ice-cold PBS and protein was extracted in a lysis buffer \[50 mmol/L Tris-HCl, pH 7.4, containing 150 mmol/L NaCl, 5 mmol/L ethylenediamine tetraacetic acid, 10% glycerol, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1% NP-40, protease inhibitor cocktail (Sigma-Aldrich), tris-buffered saline, 8% sodium dodecyl sulphate, 8 mol/L urea\]. Protein concentration was determined with BCA Protein Assay Kit (Pierce, Rocford, Illinois, USA). Protein 20 μg was loaded onto sodium dodecyl sulfate polyacrylamide gel electropheresis and transferred to a nitrocellulose membrane. After blocking with 5% non-fat dried milk, the membrane was incubated with the primary antibodies including rabbit anti-Akt (1:1 000), rabbit anti-p-Akt (1:500) and anti-β-actin (1:500) overnight at 4°C. After washes, the membrane was incubated with a horseradish peroxidase conjugated goat anti-rabbit IgG antibody (1:5 000) at room temperature for 1 hour. The desired target bands were exposed to X-ray film and then developed using ECL detection kit (BioRad, Seoul, South Korea). The band density was measured with a densitometer (GS700 model, BioRad, Seoul, South Korea).

### Statistical analysis {#sec3-5}

Results were expressed as mean ± SD. Mann-Whitney *U* tests were applied to evaluate the differences among the variables. A value of *P* \< 0.05 was considered to be statistically significant.
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